Ca 2 signatures, decoded by CaMs, CDPKs, and CBLs, emerge as key regulators of metabolic plasticity, linking nutrient sensing with hormonal and transcriptional responses
Ensure proper injection technique
J., Calcutt, N
Tirzepatide 2.5 mg activates both GLP-1 and GIP receptors, while semaglutide 0.25 mg activates only GLP-1 receptors
Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
Collecting medical records and analyzing them with the help of healthcare professionals